Janice Hitchcock, PhD, has extensive experience in regulatory affairs and drug development, with over 25 years in the pharmaceutical industry. Dr. Hitchcock joined Acumen in 2018 to lead regulatory strategy for ACU193. She was previously at Eli Lilly and Company for 17 years, where she was regulatory affairs director responsible for drug development programs and supported several public-private collaborations in Alzheimer’s disease. Dr. Hitchcock received two Lilly Research President’s Awards: one for establishing regulatory recommendations for development of biologics, and the other for engaging external stakeholders on Alzheimer’s regulatory policy. She was also named one of Lilly’s top 100 Innovators for her contributions to the first clinical trial in preclinical Alzheimer’s. She received her PhD in Psychology from Yale University, and headed a behavioral pharmacology laboratory for 10 years at Hoechst Marion Roussel/Aventis. Dr. Hitchcock is also co-author of several patents.